165 related articles for article (PubMed ID: 36249775)
1. Clinical outcomes of gemcitabine-loaded callispheres drug-eluting beads for patients with advanced and inoperable lung cancer: A case series study.
Bi Y; Zhang B; Ren J; Han X; Wu W
Front Pharmacol; 2022; 13():992526. PubMed ID: 36249775
[No Abstract] [Full Text] [Related]
2. Efficacy and safety of raltitrexed-eluting CalliSpheres
Sun Z; Jiao D; Fang Y; Liu Y; Xu K; Zhang C; Huang Y; Han X
Ther Adv Med Oncol; 2024; 16():17588359241229661. PubMed ID: 38362379
[TBL] [Abstract][Full Text] [Related]
3. The safety and efficacy of oxaliplatin-loaded drug-eluting beads transarterial chemoembolization for the treatment of unresectable or advanced lung cancer.
Bi Y; Li F; Ren J; Han X
Front Pharmacol; 2022; 13():1079707. PubMed ID: 36518678
[No Abstract] [Full Text] [Related]
4. The efficacy of drug-eluting beads bronchial arterial chemoembolization loaded with gemcitabine for treatment of non-small cell lung cancer.
Bie Z; Li Y; Li B; Wang D; Li L; Li X
Thorac Cancer; 2019 Sep; 10(9):1770-1778. PubMed ID: 31321919
[TBL] [Abstract][Full Text] [Related]
5. Oxaliplatin Eluting CalliSpheres Microspheres for the Treatment of Unresectable or Recurrent Hepatocellular Carcinoma.
Bi Y; Ren K; Ren J; Ma J; Han X
Front Pharmacol; 2022; 13():923585. PubMed ID: 36034827
[No Abstract] [Full Text] [Related]
6. Clinical outcomes of doxorubicin-eluting CalliSpheres® beads-transarterial chemoembolization for unresectable or recurrent esophageal carcinoma.
Bi Y; Shi X; Ren J; Yi M; Han X; Song M
BMC Gastroenterol; 2021 May; 21(1):231. PubMed ID: 34020608
[TBL] [Abstract][Full Text] [Related]
7. Pirarubicin-loaded CalliSpheres® drug-eluting beads for the treatment of patients with stage III-IV lung cancer.
Bi Y; Shi X; Yi M; Han X; Ren J
Acta Radiol; 2022 Mar; 63(3):311-318. PubMed ID: 33615822
[TBL] [Abstract][Full Text] [Related]
8. Transarterial chemoembolization of unresectable renal cell carcinoma with doxorubicin-loaded CalliSpheres drug-eluting beads.
Bi Y; Shi X; Ren J; Yi M; Han X
Sci Rep; 2022 May; 12(1):8136. PubMed ID: 35581365
[TBL] [Abstract][Full Text] [Related]
9. Transarterial chemoembolization with doxorubicin-loaded beads for inoperable or recurrent colorectal cancer.
Bi Y; Shi X; Ren J; Yi M; Han X; Song M
Abdom Radiol (NY); 2021 Jun; 46(6):2833-2838. PubMed ID: 33386908
[TBL] [Abstract][Full Text] [Related]
10. Preliminary outcomes of raltitrexed eluting bead-transarterial chemoembolization using Callispheres® beads for gastrointestinal adenocarcinoma liver metastasis.
Bi Y; Jiao D; Wang Y; Han X; Ren J
World J Surg Oncol; 2022 Jul; 20(1):229. PubMed ID: 35821043
[TBL] [Abstract][Full Text] [Related]
11. CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study.
Wu B; Zhou J; Ling G; Zhu D; Long Q
World J Surg Oncol; 2018 Mar; 16(1):69. PubMed ID: 29587773
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, safety, and prognostic factors of drug-eluting beads transarterial chemoembolization using CalliSpheres in treating huge hepatocellular carcinoma patients.
Wang Z; Mu K; Lv Y; Zhao L; Li B; Hao Y; Wang N
Ir J Med Sci; 2022 Dec; 191(6):2493-2499. PubMed ID: 35064533
[TBL] [Abstract][Full Text] [Related]
13. Callispheres® drug-eluting beads transarterial chemoembolization might be an efficient and safety down-staging therapy in unresectable liver cancer patients.
Peng N; Mao L; Tao Y; Xiao K; Yuan G; He S
World J Surg Oncol; 2022 Aug; 20(1):254. PubMed ID: 35941634
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of CalliSpheres
Wu X; Ying S; Huang J; Shi C; Ji J; Peng Z; Zhou G; Sun Z; Sun J; Yu W; Hu W; Zhang X; Zhou J; Shao G; Yu Z; Hou Q; Gu W; Li T; Xie X; Cao G; Du H; Zhu D; Xu H; Han J; Ji W; Fang J; Li L; Zheng J; Luo J; Chen Y; Hu T; Hu H; Guo X
Transl Cancer Res; 2019 Aug; 8(4):1199-1216. PubMed ID: 35116862
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Treatment Response, Survival Profiles, as Well as Safety Profiles Between CalliSpheres
Duan X; Liu J; Han X; Ren J; Li H; Li F; Ju S
Front Oncol; 2021; 11():793581. PubMed ID: 35127501
[TBL] [Abstract][Full Text] [Related]
16. Callispheres drug-eluting bead transhepatic artery chemoembolization with oral delivery of sorafenib for the treatment of unresectable liver cancer.
Wang W; Li F; Gan P; Li B; Li S
Front Surg; 2022; 9():981116. PubMed ID: 36117819
[TBL] [Abstract][Full Text] [Related]
17. Clinical Outcomes of Drug-Eluting Bead Transarterial Chemoembolization Loaded with Raltitrexed for the Treatment of Unresectable or Recurrent Hepatocellular Carcinoma.
Bi Y; Jiao D; Ren J; Han X
Can J Gastroenterol Hepatol; 2022; 2022():2602121. PubMed ID: 36051250
[TBL] [Abstract][Full Text] [Related]
18. A comparative study of efficacy and safety of transarterial chemoembolization with CalliSpheres and conventional transarterial chemoembolization in treating unresectable intrahepatic cholangiocarcinoma patients.
Sun T; Zhang W; Chen L; Ren Y; Liu Y; Zheng C
J Cancer; 2022; 13(4):1282-1288. PubMed ID: 35281867
[No Abstract] [Full Text] [Related]
19. CalliSpheres® drug-eluting beads (DEB) transarterial chemoembolization (TACE) is equally efficient and safe in liver cancer patients with different times of previous conventional TACE treatments: a result from CTILC study.
Zhang X; Zhou J; Zhu DD; Huang J; Sun JH; Li TF; Shi CS; Sun ZC; Hou QM; Peng ZY; Yu WQ; Ji JS; Gu WJ; Zhou GH; Xie XX; Guo XH; Cao GH; Yu ZH; Xu HH; Fang J; Ying SH; Hu WH; Ji WB; Han J; Wu X; Zheng JP; Luo J; Chen YT; Hu TY; Li L; Hu HJ; Du HJ; Shao GL
Clin Transl Oncol; 2019 Feb; 21(2):167-177. PubMed ID: 30003530
[TBL] [Abstract][Full Text] [Related]
20. Short-term efficacy and safety of callispheres drug-loaded microsphere embolization in primary hepatocellular carcinoma.
Li J; Wang N; Shi C; Liu Q; Song J; Ye X
J Cancer Res Ther; 2021 Jul; 17(3):733-739. PubMed ID: 34269307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
